PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"31267482","Naldemedine: A Review in Opioid-Induced Constipation","Blair HA.","Drugs. 2019 Jul;79(11):1241-1247. doi: 10.1007/s40265-019-01160-7.","Blair HA","Drugs","2019","2019/07/04","","","10.1007/s40265-019-01160-7"
"31183560","A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting","Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M.","Support Care Cancer. 2020 Mar;28(3):1083-1088. doi: 10.1007/s00520-019-04884-0. Epub 2019 Jun 11.","Sato J","Support Care Cancer","2020","2019/06/12","","","10.1007/s00520-019-04884-0"
"30851171","Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis","Esmadi M, Ahmad D, Hewlett A.","J Gastrointestin Liver Dis. 2019 Mar;28(1):41-46. doi: 10.15403/jgld.2014.1121.281.any.","Esmadi M","J Gastrointestin Liver Dis","2019","2019/03/10","","","10.15403/jgld.2014.1121.281.any"
"30821019","Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation","Kanemasa T, Koike K, Arai T, Ono H, Horita N, Chiba H, Nakamura A, Morioka Y, Kihara T, Hasegawa M.","Neurogastroenterol Motil. 2019 May;31(5):e13563. doi: 10.1111/nmo.13563. Epub 2019 Feb 28.","Kanemasa T","Neurogastroenterol Motil","2019","2019/03/02","PMC6850587","","10.1111/nmo.13563"
"30770183","Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting μ-opioid receptor antagonist","Watari R, Matsuda A, Ohnishi S, Hasegawa H.","Drug Metab Pharmacokinet. 2019 Apr;34(2):126-133. doi: 10.1016/j.dmpk.2018.12.002. Epub 2018 Dec 23.","Watari R","Drug Metab Pharmacokinet","2019","2019/02/17","","","10.1016/j.dmpk.2018.12.002"
"30652502","A meta-analysis of naldemedine for the treatment of opioid-induced constipation","Song X, Wang D, Qu X, Dong N, Teng S.","Expert Rev Clin Pharmacol. 2019 Feb;12(2):121-128. doi: 10.1080/17512433.2019.1570845. Epub 2019 Jan 24.","Song X","Expert Rev Clin Pharmacol","2019","2019/01/18","","","10.1080/17512433.2019.1570845"
"30446313","Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects","Inagaki M, Kume M, Tamura Y, Hara S, Goto Y, Haga N, Hasegawa T, Nakamura T, Koike K, Oonishi S, Kanemasa T, Kai H.","Bioorg Med Chem Lett. 2019 Jan 1;29(1):73-77. doi: 10.1016/j.bmcl.2018.11.007. Epub 2018 Nov 7.","Inagaki M","Bioorg Med Chem Lett","2019","2018/11/18","","","10.1016/j.bmcl.2018.11.007"
"30351180","Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects","Ohnishi S, Fukumura K, Kubota R, Wajima T.","Xenobiotica. 2019 Sep;49(9):1044-1053. doi: 10.1080/00498254.2018.1536815. Epub 2019 Jan 4.","Ohnishi S","Xenobiotica","2019","2018/10/24","","","10.1080/00498254.2018.1536815"
"30280262","Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine","Kubota R, Fukumura K, Wajima T.","Pharm Res. 2018 Oct 2;35(11):225. doi: 10.1007/s11095-018-2501-7.","Kubota R","Pharm Res","2018","2018/10/04","PMC6182381","","10.1007/s11095-018-2501-7"
"30189347","Opioid receptors in the GI tract: targets for treatment of both diarrhea and constipation in functional bowel disorders?","Pannemans J, Corsetti M.","Curr Opin Pharmacol. 2018 Dec;43:53-58. doi: 10.1016/j.coph.2018.08.008. Epub 2018 Sep 3.","Pannemans J","Curr Opin Pharmacol","2018","2018/09/07","","","10.1016/j.coph.2018.08.008"
"30042276","[A New Twist on the Administration of Naldemedine for Opioid-Induced Constipation in an Outpatient]","Shikada Y, Emi Y, Kometani T, Ochiai T, Fujii M, Noda Y, Kajiwara M, Ikeda M, Asonuma S, Mori M.","Gan To Kagaku Ryoho. 2018 Jul;45(7):1075-1079.","Shikada Y","Gan To Kagaku Ryoho","2018","2018/07/26","","",""
"29869799","Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care","Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.","Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD006332. doi: 10.1002/14651858.CD006332.pub3.","Candy B","Cochrane Database Syst Rev","2018","2018/06/06","PMC6513061","","10.1002/14651858.CD006332.pub3"
"29621475","Management of Opioid-Induced Constipation in Patients with Malignancy","Garcia JM, Shamliyan TA.","Am J Med. 2018 Sep;131(9):1041-1051.e3. doi: 10.1016/j.amjmed.2018.02.038. Epub 2018 Apr 2.","Garcia JM","Am J Med","2018","2018/04/06","","","10.1016/j.amjmed.2018.02.038"
"29419653","Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study","Webster LR, Nalamachu S, Morlion B, Reddy J, Baba Y, Yamada T, Arjona Ferreira JC.","Pain. 2018 May;159(5):987-994. doi: 10.1097/j.pain.0000000000001174.","Webster LR","Pain","2018","2018/02/09","PMC5916485","","10.1097/j.pain.0000000000001174"
"29406802","Reply to Y. Yagi et al","Katakami N, Yokota T, Tada Y.","J Clin Oncol. 2018 Apr 1;36(10):1050. doi: 10.1200/JCO.2017.77.0925. Epub 2018 Feb 6.","Katakami N","J Clin Oncol","2018","2018/02/07","","","10.1200/JCO.2017.77.0925"
"29406801","Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer","Yagi Y, Kosugi K, Tanimoto T.","J Clin Oncol. 2018 Apr 1;36(10):1049-1050. doi: 10.1200/JCO.2017.76.9349. Epub 2018 Feb 6.","Yagi Y","J Clin Oncol","2018","2018/02/07","","","10.1200/JCO.2017.76.9349"
"29324623","New Drugs 2018, part 1","Hussar DA.","Nursing. 2018 Feb;48(2):36-44. doi: 10.1097/01.NURSE.0000529803.83288.e1.","Hussar DA","Nursing","2018","2018/01/12","","","10.1097/01.NURSE.0000529803.83288.e1"
"29210822","PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONISTS","Martinez-Cox S, Espinosa K, Friece C, Rahman A.","Gastroenterol Nurs. 2017 Nov/Dec;40(6):517-522. doi: 10.1097/SGA.0000000000000326.","Martinez-Cox S","Gastroenterol Nurs","2017","2017/12/07","","","10.1097/SGA.0000000000000326"
"29186083","Naldemedine (Symproic) for opioid-induced constipation","","Med Lett Drugs Ther. 2017 Dec 4;59(1535):196-198.","","Med Lett Drugs Ther","2017","2017/11/30","","",""
"29092627","Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain","Murphy JA, Sheridan EA.","Ann Pharmacother. 2018 Apr;52(4):370-379. doi: 10.1177/1060028017739637. Epub 2017 Nov 2.","Murphy JA","Ann Pharmacother","2018","2017/11/03","","","10.1177/1060028017739637"
"28968171","Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer","Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N.","J Clin Oncol. 2017 Dec 1;35(34):3859-3866. doi: 10.1200/JCO.2017.73.0853. Epub 2017 Oct 2.","Katakami N","J Clin Oncol","2017","2017/10/03","","","10.1200/JCO.2017.73.0853"
"28960888","Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers","Fukumura K, Yokota T, Baba Y, Arjona Ferreira JC.","Clin Pharmacol Drug Dev. 2018 Jun;7(5):474-483. doi: 10.1002/cpdd.387. Epub 2017 Sep 27.","Fukumura K","Clin Pharmacol Drug Dev","2018","2017/09/30","","","10.1002/cpdd.387"
"28576452","Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","Hale M, Wild J, Reddy J, Yamada T, Arjona Ferreira JC.","Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555-564. doi: 10.1016/S2468-1253(17)30105-X. Epub 2017 May 30.","Hale M","Lancet Gastroenterol Hepatol","2017","2017/06/04","","","10.1016/S2468-1253(17)30105-X"
"28483411","Naldemedine effective in treating opioid-induced constipation","Brower V.","Lancet Oncol. 2017 Jun;18(6):e306. doi: 10.1016/S1470-2045(17)30320-0. Epub 2017 May 5.","Brower V","Lancet Oncol","2017","2017/05/10","","","10.1016/S1470-2045(17)30320-0"
"28466424","Naldemedine: First Global Approval","Markham A.","Drugs. 2017 May;77(8):923-927. doi: 10.1007/s40265-017-0750-0.","Markham A","Drugs","2017","2017/05/04","","","10.1007/s40265-017-0750-0"
"28445097","Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer","Katakami N, Oda K, Tauchi K, Nakata K, Shinozaki K, Yokota T, Suzuki Y, Narabayashi M, Boku N.","J Clin Oncol. 2017 Jun 10;35(17):1921-1928. doi: 10.1200/JCO.2016.70.8453. Epub 2017 Apr 26.","Katakami N","J Clin Oncol","2017","2017/04/27","","","10.1200/JCO.2016.70.8453"
"28371937","A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain","Webster LR, Yamada T, Arjona Ferreira JC.","Pain Med. 2017 Dec 1;18(12):2350-2360. doi: 10.1093/pm/pnw325.","Webster LR","Pain Med","2017","2017/04/04","PMC5914456","","10.1093/pm/pnw325"
